Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints - Reuters

Reuters | Dec. 20, 2024, 12:52 p.m. | Original
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters
Republicans mount third attempt to fund government, shutdown looms - Reuters Spire's sale of ship tracking arm raises antitrust concerns - Reuters